



**FOR IMMEDIATE RELEASE**

**Contact:** Donna Richardson  
**Phone:** 216-338-6412  
**Email:** donna@collamedixinc.com

**CollaMedix Inc. announces oversubscribed Seed Round  
Prepares to enter the Sports Medicine Market**

CLEVELAND, OHIO, Sept. 2023. CollaMedix® Inc. is pleased to announce the initial closing of a Simple Agreement for Future Equity (SAFE) which is oversubscribed at \$1.4M. To date CollaMedix raised \$5.5M in funding including \$4.1M in National Science Foundation and National Institutes of Health grants. Funds will be used to complete the 510(k) submission of the company's first pure collagen product, the CollaSleeve® for rotator cuff repair (RCR) augmentation, with market clearance expected in 2024. The company intends to introduce a family of proprietary electrocompacted collagen based products with CollaFabric® in Sports Medicine.

Donna Richardson, CEO stated, "We are grateful for the support of our investors including dsm-firmenich Venturing, the corporate venture capital arm of dsm-firmenich, Heerlen, Netherlands, and ProMedica Ventures, Toledo, OH, for their participation in the SAFE along with our valued private investors. This funding positions CollaMedix to enter the Sports Medicine sector in 2024. Our novel products fabricated with advanced pure collagen biofabrics compete by improving the quality of healing creating a new era in high value collagen."

Subba Shankar, PhD, CTO commented: "CollaMedix's pure collagen threads with tensile strength (CollaFabric®) are braided into scaffolds (CollaSleeve®) which demonstrate a unique deposition of *de novo* tendinous tissue within the implant. Animal studies indicate significant tendon thickening with CollaSleeve compared to other RCR products."

If you would like more information please contact Donna Richardson, CEO, CollaMedix Inc. at [donna@collamedixinc.com](mailto:donna@collamedixinc.com); or visit [www.collamedixinc.com](http://www.collamedixinc.com). A Term Sheet and Offering Memorandum are available for qualified investors.

CollaMedix®, a start-up medical device company, develops novel electrocompacted technology and is commercializing products with CollaFabric® a pure collagen biofabric or scaffold to improve the quality of soft tissue healing.

***CollaFabric® a novel pure collagen biofabric improving the quality of healing***

